Catalent, Inc. (CTLT)'s portfolio has seen significant developments lately. Swedish firm
Novo Holdings recently finalized a
$16.5 billion acquisition of the American contract manufacturer at a 47.5% premium to shareholders. This comes as they also received unconditional approval for the transaction from the
European Commission. Following the buyout, Catalent's CEO will remain in charge of the contract drug manufacturer. Ahead of the substantial deal closure, Catalent missed its Q1 revenue estimates yet managed to drum up gains after reports circulated, indicating the imminent close of the acquisition deal. In similar news,
Catalent has made an agreement to
sell its Somerset, NJ oral solids facility. Amid these developments,
CTLT is experiencing headwinds as it faces
financial performance scrutiny and investigation from Bronstein, Gewirtz & Grossman, LLC, while preparing to be replaced in the S&P 500 Index by Lennox International. Despite these challenges, both companies have pronounced their satisfaction with cleared regulatory conditions and potential future collaborative opportunities.
Catalent CTLT News Analytics from Thu, 16 Feb 2017 08:00:00 GMT to Fri, 14 Feb 2025 07:26:00 GMT -
Rating 7
- Innovation 2
- Information 8
- Rumor -2
